Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R.
Nijland HM, et al. Among authors: aarnoutse re.
Clin Infect Dis. 2006 Oct 1;43(7):848-54. doi: 10.1086/507543. Epub 2006 Aug 22.
Clin Infect Dis. 2006.
PMID: 16941365
Free article.